Introduction {#s1}
============

Heart failure (HF) is the end-stage of various heart diseases, and it represents a major health problem owing to its high prevalence, morbidity, mortality and significant health-care costs [@pone.0037659-Dickstein1]--[@pone.0037659-Hunt1]. β-blockers are mainstay of current treatment of heart failure (HF) in guideline, for their administration has beneficial effects on left ventricular (LV) function and prognosis [@pone.0037659-Dickstein1]--[@pone.0037659-Metra1]. However, in clinical practice, the response to β-blocker therapy and prognosis of HF are variable among patients. The purpose of diagnosing and treating HF is bringing about a reduction of mortality and morbidity. It is therefore important to identify the risk factors for HF so that preventive measurements can be undertaken early; and anticipation the response to β-blockers would help the physicians to make therapeutic decision. Thus there are needs for risk stratification tools of HF and predictors of response to β-blockers treatment, which are still challenges in the real world.

As the targets of endogenous catecholamines and β-blockers, β1 adrenergic receptor is known to play a pivotal role in the progression and treatment of HF [@pone.0037659-Lohse1]. Two common functional polymorphisms of the β1-AR, Ser49Gly and Arg389Gly have been considered as predictors of susceptibility to HF, response to β-blockers therapy and even prognosis of HF in some publications. However, being limited by small sample size, the results are controversial. Thus, we performed this meta-analysis of all the available studies to evaluate the impacts of β1 AR polymorphisms on susceptibility to HF, response to β-blocker therapy, and prognosis. It may provide information for further investigation on individualized HF prevention and treatment.

Methods {#s2}
=======

Search and Selection Process {#s2a}
----------------------------

Electronic searches by PubMed, Cochrane Library, and Chinese Biomedical Disc were used to identify published articles on β1 AR polymorphisms and heart failure. We combined search terms for "β1 receptor genetic polymorphism", "ADRB1 polymorphism", "Ser49Gly", "Arg389Gly", and all of the studies were published before August 2011. When more than one of the same patient population was included in several publications, only the most recent or complete study was identified in this meta-analysis.

Inclusion Criteria {#s2b}
------------------

For the susceptibility to heart failure: (1) case--control studies, (2) evaluating the association between the β1 adrenergic receptor genetic polymorphisms and HF risk, (3) the diagnosis of HF was made according to the World Health Organization criteria, based on the presence of the typical clinical signs and symptoms of HF with left ventricular dysfunction.

Response to β-blockers therapy: (1) The definition of HF was based on the World Health Organization criteria, (2) evaluation of β1 AR genetic polymorphisms on the reduction of heart rate (ΔHR), the changes of left ventricular ejection fraction (ΔLVEF), left ventricular end-diastolic diameter/volume (ΔLVEDd/v), left ventricular end-systolic diameter/volume (ΔLVESd/v), with at least 3 months follow up, (3) all the patients received β-blockers therapy, other medicines such as ACEI/ARB, diuretics, spironolactone, and digoxin were used when necessary.

β1 AR polymorphisms and HF prognosis: (1) The definition of HF was based on the World Health Organization criteria, (2) evaluation of β1 adrenergic receptor genetic polymorphisms on all-cause mortality or combined end-point including death, heart transplantation and hospitalization, (3) patients were followed up for more than 1 year.

All the searches were restricted to articles in English or Chinese. Case reports, editorials, and review articles were excluded.

Data Extraction {#s2c}
---------------

Two reviewers independently extracted data from published sources. The following information was extracted from each study: the first author, publication year, study design, ethnicity, sample size, distribution of genotypes, Hardy -Weinberg equilibrium (HWE) in controls, the parameters of therapy response (ΔHR, ΔLVEF, ΔLVEDd/v, and ΔLVESd/v), and the occurrence of death and combined end-point. We did not define any minimum number of subjects as required to include a study in our meta-analysis. If necessary data could not be extracted, the study authors were contacted by e-mail, with a reminder after 30 days. Disagreements were resolved by joint review and consensus.

Statistics {#s2d}
----------

Cochrane collaboration meta-analysis review methodology was used for this study [@pone.0037659-Higgins1]. The allele contrast, the recessive and dominant models were evaluated for association between the risk of heart failure and the β1 AR polymorphisms. In addition to the overall analysis, subgroup analysis for each ethnicity was also performed. Ethnicity was categorized into 3 main groups: (1) white descents, (2) East Asian descents, and (3) black descents. The distribution of the genotypes in the control group was tested for Hardy--Weinberg equilibrium [@pone.0037659-Higgins1], a *P*\<0.05 was considered that the distribution of genotypes in the control group deviated from HWE. Studies with controls not in HWE were subjected to a sensitivity analysis.

In the meta-analysis of influence on HF patients therapy response and prognosis, comparisons of therapy response parameters (ΔHR, ΔLVEF, ΔLVEDd/v, ΔLVESd/v) and prognosis (mortality and combined end-point) between Gly49 carriers (Gly49Gly + Ser49Gly) and Ser49 homozygotes, Gly389 carriers (Gly389Gly + Arg389Gly) and Arg389 homozygotes were carried out respectively.

The analysis was carried out using Review Manager statistical software (RevMan version 5.0.2; The Nordic Cochrane Center, Regshospitalet). Pooled relative risk (RR) and associated 95% confidence intervals (CIs) were calculated for the risk and prognosis of HF. The therapy response was evaluated with weighted mean difference (WMD) for ΔHR and ΔLVEF, or standardized mean difference (SMD) for ΔLVEDd/LVEDv, ΔLVESd/LVESv. All tests and CIs were 2-sided, and a *P*\<0.05 was considered statistically significant.

The presence of heterogeneity across studies was evaluated. The fixed-model (Mantel--Haenszel) was used when smaller heterogeneity were available (*P* ~h~ \<0.1), otherwise the random model (DerSimonian and Laird) was used [@pone.0037659-Higgins2]. Heterogeneity was assessed with I^2^ test, which described the proportion of variation in the log RR that is attributable to genuine differences across studies rather than to random error. I^2^ took values between 0% and 100% with higher values denoting greater degree of heterogeneity (I^2^ = 0% to 25%: no heterogeneity; I^2^ = 25% to 50%: moderate heterogeneity; I^2^ = 50% to 75%: large heterogeneity; I^2^ = 75% to 100%: extreme heterogeneity). Publication bias was assessed using a funnel plot of effect size against standard error.

Results {#s3}
=======

Eligible Studies {#s3a}
----------------

A total of 345 potentially eligible studies were identified, of which 291 were excluded after reviewing the study abstracts. The retrieved studies were then read in their entirety to assess their appropriateness for inclusion in the meta-analysis. As shown in [Table 1](#pone-0037659-t001){ref-type="table"}, fourteen studies were included for relationship between β1 AR polymorphisms and susceptibility to HF [@pone.0037659-Wang1]--[@pone.0037659-Podlowski1], while 8 studies evaluated the impact of β1 AR polymorphisms on HF therapy response to β-blocker [@pone.0037659-Yu1], [@pone.0037659-Metra2]--[@pone.0037659-MialetPerez1], and 10 studies provided information on association between prognosis and β1 AR polymorphisms [@pone.0037659-Wang1], [@pone.0037659-Biolo1], [@pone.0037659-Magnusson1], [@pone.0037659-Liggett1], [@pone.0037659-MialetPerez1]--[@pone.0037659-Shin1]. The reasons why studies were excluded were shown in [Figure 1](#pone-0037659-g001){ref-type="fig"}.

10.1371/journal.pone.0037659.t001

###### The characters of the 27 eligible studies.

![](pone.0037659.t001){#pone-0037659-t001-1}

  Authors                                              Year        Region         Ethnicity            Type of study           Sample size(case/control)    Main assessments                                    Parameter
  --------------------------------------------------- ------ ------------------- ------------ ------------------------------- --------------------------- --------------------- -------------------------------------------------------------------------
  Wang L et al [@pone.0037659-Wang1]                   2010         China         East Asian           case-control                     430/468            Ser49Gly, Arg389Gly            risk of HF, mortality and combined endpoint in2 years
  Paczkowska A et al [@pone.0037659-Paczkowska1]       2009        Poland           White              case-control                     97/105             Ser49Gly, Arg389Gly                                 risk of HF
  Woodiwiss AJ et al [@pone.0037659-Woodiwiss1]        2008     South African       Black              case-control                     403/429                 Arg389Gly                                      risk of HF
  Biolo A et al [@pone.0037659-Biolo1]                 2008        Brazil           mixed              case-control                     201/141            Ser49Gly, Arg389Gly                    risk of HF, mortality in 39.8 months
  Yu WP et al [@pone.0037659-Yu1]                      2006         China         East Asian           case-control                     105/100                 Arg389Gly        risk of HF; ΔHR, ΔLVEF, ΔLVEDd, ΔLVESd with3 months β-blocker treatment
  Nonen S et al [@pone.0037659-Nonen1]                 2005         Japan         East Asian           case-control                     91/119             Ser49Gly, Arg389Gly                                 risk of HF
  Covolo L et al [@pone.0037659-Covolo1]               2004         Italy           White              case-control                     256/230            Ser49Gly, Arg389Gly                                 risk of HF
  Magnusson Y et al [@pone.0037659-Magnusson1]         2005        Sweden           White              case-control                     375/492            Ser49Gly, Arg389Gly                      risk of HF, mortality in 5 years
  Small KM et al [@pone.0037659-Small1]                2002        America          mixed              case-control                     159/189                 Arg389Gly                                      risk of HF
  Iwai C et al [@pone.0037659-Iwai1]                   2002         Japan         East Asian           case-control                     163/157                 Arg389Gly                                      risk of HF
  Forleo C et al [@pone.0037659-Forleo1]               2007         Italy           White              case-control                     189/378            Ser49Gly, Arg389Gly                                 risk of HF
  Tesson F et al [@pone.0037659-Tesson1]               1999        France           White              case-control                     426/395                 Arg389Gly                                      risk of HF
  Fragoso JM et al [@pone.0037659-Fragoso1]            2006        Mexico          Mexican             case-control                      47/93             Ser49Gly, Arg389Gly                                 risk of HF
  Podlowski S et al [@pone.0037659-Podlowski1]         2000        Germany          White              case-control                      37/40             Ser49Gly, Arg389Gly                                 risk of HF
  Metra M et al [@pone.0037659-Metra2]                 2010         Italy           White               prospective                       183                   Arg389Gly              ΔHR, ΔLVEF, ΔLVEDv, ΔLVESv with 6 monthsβ-blocker treatment
  Chen L et al [@pone.0037659-Chen1]                   2007       Australia         White      prospective and retrospective              135              Ser49Gly, Arg389Gly            ΔLVEF, ΔLVEDd, ΔLVESd with 1 year β-blocker treatment
  Luo M et al [@pone.0037659-Luo1]                     2007         China         East Asian            prospective                       156                   Arg389Gly                    ΔLVEF, ΔLVESd with 3 months β-blocker treatment
  Liggett SB et al [@pone.0037659-Liggett1]            2006        America          Mixed               prospective                       515                   Arg389Gly              ΔHR, ΔLVEF with β-blocker treatment, mortalityin 12 months
  Terra SG et al [@pone.0037659-Liggett1]              2005        America          Mixed               prospective                       54               Ser49Gly, Arg389Gly         ΔHR, ΔLVEF, ΔLVEDd, ΔLVESd with 3 monthsβ-blocker treatment
  de Groote P et al [@pone.0037659-deGroote2]          2005        France           White               prospective                       199              Ser49Gly, Arg389Gly                ΔHR, ΔLVEF with 3 months β-blocker treatment
  Mialet Perez J et al [@pone.0037659-MialetPerez1]    2003        America            NS               retrospective                      224                   Arg389Gly                       ΔLVEF after 6 months β-blocker treatment
  Petersen M et al [@pone.0037659-MialetPerez1]        2011        Denmark          White              retrospective                      305                   Arg389Gly                                mortality in 6.7 years
  Leineweber K et al [@pone.0037659-Leineweber1]       2010        Germany          White               prospective                       226              Ser49Gly, Arg389Gly                           mortality in 45 months
  Cresci S et al [@pone.0037659-Cresci1]               2009        America          Mixed               prospective                      1133                   Arg389Gly                     mortality and combined endpoint in 6.5 years
  White HL et al [@pone.0037659-White1]                2003   UK and Netherland     White              retrospective                      600                   Arg389Gly                            combined endpoint in 12 months
  Forleo C et al [@pone.0037659-Forleo2]               2004         Italy           White               prospective                       171              Ser49Gly, Arg389Gly                       combined endpoint in 33 months
  Shin J et al [@pone.0037659-Shin1]                   2007        America          Mixed               prospective                       227              Ser49Gly, Arg389Gly                mortality and combined endpoint in 2.8 years

HF, heart failure; LVEF, left ventricular ejection fraction; LVEDd/v, left ventricular end diastolic diameter/volume; LVESd/v, left ventricular end systolic diameter/volume; combined endpoint, including death, heart transplantation and hospitalization; NS, not stated.

![Flow diagram of the study selection process β1-AR: β1 adrenergic receptor.](pone.0037659.g001){#pone-0037659-g001}

β1 AR Polymorphisms and Susceptibility to HF {#s3b}
--------------------------------------------

A total of 14 case-control studies [@pone.0037659-Wang1]--[@pone.0037659-Podlowski1] containing 2979 patients and 3336 controls provided data on the association between β1 AR polymorphisms and the susceptibility to HF (14 for Arg389Gly and 8 for Ser49Gly, as shown in [Table 1](#pone-0037659-t001){ref-type="table"}). The causes of HF were various, including idiopathic dilated cardiomyopathy (IDCM), hypertension and ischemic cardiomyopathy. Controls were mainly healthy population, and matched for area and ethnicity. Genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in all the publications. Studies were conducted in various populations of racial descent: 7 studies for whites, 4 involved East Asians, 1 study for blacks, 1 involved Mexicans, and 1 study was mixed. The distribution of genotypes in the control group deviated from HWE in 2 studies for Ser49Gly [@pone.0037659-Wang1], [@pone.0037659-Podlowski1], and then a sensitivity analysis was carried out excluding these studies to avoid possible genotyping errors and/or population stratification. The distribution of the β1 AR genotypes for cases and controls was shown in [Table 2](#pone-0037659-t002){ref-type="table"}.

10.1371/journal.pone.0037659.t002

###### The distribution of the Arg389Gly and Ser49Gly genotype for cases and controls.
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                                        Arg389Arg (or Ser49Ser)   Arg389Gly (or Ser49Gly)   Gly389Gly (or Gly49Gly)   Arg389 (or Ser49)   Gly389 (or Gly49)                               
  ------------------------ ----------- ------------------------- ------------------------- ------------------------- ------------------- ------------------- ---- ----- ----- ----- ----- ---------
  Wang L 2010               Ser49Gly              270                       338                       152                    130                  8           0    692   806   168   130   0.00048
  Wang L 2010               Arg389Gly             263                       316                       135                    139                 32           13   661   771   199   165   0.62323
  Paczkowska A 2009         Ser49Gly              76                        87                        21                     17                   0           1    173   191   21    19    0.86769
  Paczkowska A 2009         Arg389Gly             57                        50                        35                     47                   5           8    149   147   45    63    0.50042
  Woodiwiss AJ 2008         Arg389Gly             200                       210                       161                    172                 42           47   561   592   245   266   0.19305
  Biolo A 2008              Ser49Gly              146                       105                       50                     30                   5           6    342   240   60    42    0.05634
  Biolo A 2008              Arg389Gly             112                       81                        72                     52                  17           8    296   214   106   68    0.92718
  Yu WP 2006                Arg389Gly             54                        53                        42                     40                   9           7    150   146   60    54    0.88303
  Nonen S 2005              Ser49Gly              66                        83                        21                     33                   4           3    153   199   29    39     0.896
  Nonen S 2005              Arg389Gly             60                        79                        26                     35                   5           5    146   193   36    45    0.65567
  Covolo L 2004             Arg389Gly             119                       122                       116                    90                  21           18   354   334   158   126   0.8053
  Magnusson Y 2005          Ser49Gly              255                       333                       110                    148                 10           11   620   814   130   170   0.24506
  Magnusson Y 2005          Arg389Gly             218                       266                       140                    201                 15           25   576   733   170   251   0.09614
  Small KM 2002 (blacks)    Arg389Gly             43                        63                        34                     34                   4           8    120   160   42    50    0.27066
  Small KM 2002 (whites)    Arg389Gly             23                        23                        36                     48                  19           13   82    94    74    74    0.14432
  Forleo C 2007             Ser49Gly              137                       318                       51                     58                   1           2    325   694   53    62     0.711
  Forleo C 2007             Arg389Gly             100                       173                       78                     159                 11           46   278   505   100   251   0.31498
  Tesson F 1999             Arg389Gly             261                       231                       140                    136                 25           28   662   598   190   192   0.20168
  Fragoso JM 2006           Ser49Gly              25                        61                        19                     28                   3           4    69    150   25    36    0.73168
  Fragoso JM 2006           Arg389Gly             24                        69                        20                     20                   3           4    68    158   26    28    0.12488
  Iwai C 2002               Arg389Gly             88                        74                        54                     71                  21           12   230   219   96    95    0.36985
  Podlowski S 2000          Ser49Gly              31                        40                         5                      0                   1           0    67    80     7     0      --
  Podlowski S 2000          Arg389Gly             19                        21                        16                     18                   2           1    54    60    20    20    0.2059

HWE: Hardy--Weinberg Equilibrium.

The results for the associations between the β1 AR polymorphisms and the risk of HF were shown in [Table 3](#pone-0037659-t003){ref-type="table"}. In general population, the Arg389Gly polymorphism was not significantly associated with HF for all genetic models, the heterogeneity among studies was significant (Gly vs. Arg: *P* ~h~ = 0.01, I^2^ = 52%). In subgroup analysis by ethnicity, in East Asians Gly389 allele increased the susceptibility to HF (RR = 1.10; 95% CI: 1.01--1.19, *P* = 0.03), and Gly389 homozygote was significantly associated with a 35% increased risk of HF compared with Arg389 carrier (RR = 1.35; 95% CI: 1.16--1.57, *P*\<0.01); in contrast, Gly389 allele (RR = 0.94; 95% CI: 0.89--1.00, *P* = 0.06) and Gly389 homozygote (RR = 0.84; 95% CI: 0.71--1.00, *P* = 0.05) trend to decrease the risk of HF in whites. Among blacks, there was not a significant relationship between the Arg389Gly polymorphism and HF.

10.1371/journal.pone.0037659.t003

###### RRs and Heterogeneity Results for the Genetic Contrasts of Arg389Gly and Ser49Gly β1 AR Polymorphisms for HF.

![](pone.0037659.t003){#pone-0037659-t003-3}

  Polymorphism                     Ethnicity       RR (95% CI)      Studies   I^2^, %   *P* ~h~   Overall effect, *P*
  ------------------------------ ------------- ------------------- --------- --------- --------- ---------------------
  Arg389Gly                                                                                      
  Gly vs. Arg                         All       1.01 (0.95, 1.08)     14        52       0.01            0.66
                                     Asian      1.10 (1.01, 1.19)      4        26       0.25            0.03
                                     White      0.94 (0.89, 1.00)      7        38       0.14            0.06
                                     Black      1.00 (0.91, 1.10)      2         0        0.5            0.98
  Gly389 carrier vs. Arg389Arg        All       1.00 (0.93, 1.08)     14        41       0.05            0.98
                                     Asian      1.05 (0.95, 1.17)      4        35        0.2            0.31
                                     White      0.95 (0.88, 1.03)      7        34       0.17            0.19
                                     Black      0.98 (0.86, 1.12)      2         0       0.84            0.77
  Gly389Gly vs. Arg389 carrier        All       1.08 (0.93, 1.24)     14        50       0.01            0.31
                                     Asian      1.35 (1.16, 1.57)      4         0       0.48           0.0001
                                     White      0.84 (0.71, 1.00)      7         0       0.46            0.05
                                     Black      1.05 (0.87, 1.27)      2        50       0.16            0.62
  Ser49Gly                                                                                       
  Gly vs. Ser                         All       1.22 (1.04, 1.43)      8        80      \<0.01           0.02
                                  Sensitivity   1.11 (0.97, 1.27)      6        51       0.07            0.13
                                     Asian      1.18 (1.06, 1.31)      2        44       0.18            0.003
                                     White      1.34 (0.95, 1.90)      4        90      \<0.01            0.1
  Gly49 carrier vs. Ser49Ser          All       1.33 (1.03, 1.72)      8        52       0.04            0.03
                                  Sensitivity   1.25 (0.94, 1.66)      6        48       0.08            0.12
                                     Asian      1.24 (0.72, 2.13)      2        64       0.09            0.44
                                     White      1.48 (0.86, 2.57)      4        72       0.01            0.16
  Gly49Gly vs. Ser49 carrier          All       1.24 (0.74, 2.08)      8        81      \<0.01           0.42
                                  Sensitivity   1.03 (0.76, 1.39)      6         0       0.84            0.86
                                     Asian      1.72 (0.95, 3.12)      2        69       0.07            0.07
                                     White      1.08 (0.73, 1.62)      4         0       0.76            0.69

For the Ser49Gly polymorphism, overall, the heterogeneity among studies was significant (*P* ~h~\<0.01, I^2^ = 80%). The Gly49 allele significantly increased HF risk (RR = 1.22; 95% CI: 1.04--1.43, *P* = 0.02) compared with Ser49, while Gly49 carrier had significantly higher risk of HF than Ser49Ser homozygote (RR = 1.33; 95% CI: 1.03--1.72, *P* = 0.03). But neither of the associations was significant in sensitivity analysis. In ethnicity subgroup analysis, Gly49 significantly increased HF risk compared with Ser49 (RR = 1.18; 95% CI: 1.06--1.31, *P*\<0.01) in East Asians, however, it was not robust either. No association between the risk of HF and Ser49Gly polymorphism was found in whites.

β1 AR Polymorphisms and Response to β-blocker Therapy {#s3c}
-----------------------------------------------------

Eight studies [@pone.0037659-Yu1], [@pone.0037659-Metra2]--[@pone.0037659-MialetPerez1] evaluated the impact of β1 AR polymorphisms on response to β-blocker therapy: 2 involved East Asians, 3 studies for whites, and 3 studies were mixed (Americans, mainly composed of blacks and Caucasians). ΔHR and parameters of LV remodeling (ΔLVEF, ΔLVEDd/v, and ΔLVESd/v) were used to assess the response to β-blocker therapy with at least 3 months follow up. All the 1561 patients with a LVEF ≤45% received concomitant drug therapy, which included β-blocker, angiotensin converting-enzyme (ACE) inhibitor (or an angiotensin receptor blocker if the ACE inhibitor was not tolerated), spironolactone, digoxin, duretics and so on. The kinds of β-blockers were various, comprised selective β1-blockers (metoprolol, bisoprolol) and non-selective β-blockers (carvidilol, bucindolol). And the dose of β-blockers was the target dose according to guideline or a maximum tolerated dose. The LVEF, LVEDd/v and LVESd/v were measured with echocardiogram or radionuclide ventriculography.

Five studies [@pone.0037659-Yu1], [@pone.0037659-Metra2], [@pone.0037659-Liggett1]--[@pone.0037659-deGroote2] including 1056 patients provide information on the reduction of heart rate after β-blocker therapy. There was not a significant difference in the reduction of heart rate between Arg389 homozygotes and Gly389 carriers (WMD = −0.47, 95% CI: −1.65--0.71, *P* = 0.43, [Figure 2A](#pone-0037659-g002){ref-type="fig"}). Even in different ethnics, the HR reductions with β-blockers treatment were comparable in the Arg389 homozygotes and Gly389 carriers.

![Arg389 homozygotes vs. Gly389 carriers in different ethnics: the response to β-blockers.\
(A) the reduction of HR; (B) the improvements of LVEF; (C) the improvements of LVEDd/v; (D) the improvements of LVESd/v. Gly389 carriers: including Arg389Gly and Gly389 homozygotes; CI: confidence interval; HR: heart rate; LVEF: left ventricular ejection fraction; LVEDd/v: left ventricular end-diastolic diameter/volume; LVESd/v: left ventricular end-systolic diameter/volume.](pone.0037659.g002){#pone-0037659-g002}

Compared with Gly389 carriers, overall, there was a significant improvement in LV remodeling in Arg389 homozygotes. Eight studies [@pone.0037659-Yu1], [@pone.0037659-Metra2]--[@pone.0037659-MialetPerez1] containing 1602 patients indicated that the improvement of LVEF was better in Arg389 homozygotes (WMD = 1.83, 95% CI: 0.72--2.94, *P*\<0.01, [Figure 2B](#pone-0037659-g002){ref-type="fig"}). And another meta-analysis including 4 studies [@pone.0037659-Yu1], [@pone.0037659-Metra2], [@pone.0037659-Chen1], [@pone.0037659-Liggett1] and 477 patients showed that the LVEDd/v improvement of Arg389 homozygotes trended to be better than Gly389 carriers (SMD = −0.16, 95% CI = −0.35--0.02, *P* = 0.07, [Figure 2C](#pone-0037659-g002){ref-type="fig"}). And it was also found that the LVESd/v improvement of Arg389 homozygotes was significantly greater than Gly389 carriers (SMD = −0.20, 95% CI: −0.36-- −0.04, *P* = 0.01, [Figure 2D](#pone-0037659-g002){ref-type="fig"}) from a meta-analysis of 5 studies [@pone.0037659-Yu1], [@pone.0037659-Metra2], [@pone.0037659-Chen1], [@pone.0037659-Luo1], [@pone.0037659-Liggett1] and 633 patients.

In further subgroup analysis, it was found that the Arg389 homozygotes were associated with a better LVEF improvement in East Asians (WMD = 2.63, 95% CI: 1.85--3.40, P\<0.01, [Figure 2B](#pone-0037659-g002){ref-type="fig"}) and mixed population (WMD = 1.81, 95% CI: 0.72--2.91, P\<0.01, [Figure 2B](#pone-0037659-g002){ref-type="fig"}); while among white patients, the Arg389 homozygotes made a better improvement of LVESd/v (SMD = −0.24, 95% CI = −0.46-- −0.01, P = 0.04, [Figure 2D](#pone-0037659-g002){ref-type="fig"}) and also a trend of better improvement of LVEDd/v (SMD = −0.19, 95% CI = −0.41--0.03, P = 0.09, [Figure 2C](#pone-0037659-g002){ref-type="fig"} ).

In another subgroup analysis, the LVEF improvement of Arg389 homozygotes was significantly greater than Gly389 carriers (SMD = 2.08, 95% CI: 0.94--3.22, *P*\<0.01, [Figure 3](#pone-0037659-g003){ref-type="fig"}) in patients treated with selective β1-blockers, but non-selective β-blockers did not achieve different LVEF improvements between Arg389 homozygotes and Gly389 carriers (SMD = 1.90, 95% CI: −0.46--4.26, *P* = 0.11, [Figure 3](#pone-0037659-g003){ref-type="fig"}).

![Arg389 homozygotes vs. Gly389 carriers with selective or non-selective β-blockers: the improvements of LVEF.\
Gly389 carrier: including Arg389Gly and Gly389 homozygotes; CI: confidence interval; LVEF: left ventricular ejection fraction.](pone.0037659.g003){#pone-0037659-g003}

β1 AR Polymorphisms and Prognosis of HF {#s3d}
---------------------------------------

A total of 10 studies evaluated the impact of β1 AR polymorphisms on HF mortality and/or combined endpoint incidence. In 2 of them, the kind of β-blocker was fixed (BEST research: bucindolol, MERIT-HF: metoprolol CR/XL). Patients in the other 8 studies were mostly treated with β-blockers (at least 70%), and the kinds and dose of β-blockers (metoprolol, bisoprolol, carvidilol and other β-blocker) were decided by the subjects' physicians. The patients were mostly whites in the 10 studies, in which the causes of HF were various (ischemic/IDCM/hypertension).

There was no significant difference between Arg389 homozygotes and Gly389 carriers in all-cause mortality (RR = 1.07; 95% CI: 0.94--1.21, *P* = 0.29, [Figure 4A](#pone-0037659-g004){ref-type="fig"}) or combined end-point (RR = 1.05; 95% CI: 0.95--1.16, *P* = 0.37, [Figure 4B](#pone-0037659-g004){ref-type="fig"}). And all-cause mortality of Ser49 homozygotes was not significantly different with Gly49 carriers (RR = 1.36; 95% CI: 0.93--2.01, *P* = 0.12, [Figure 4C](#pone-0037659-g004){ref-type="fig"}), so it was with the combined end-point (RR = 0.94; 95% CI: 0.61--1.44, *P* = 0.76, [Figure 4D](#pone-0037659-g004){ref-type="fig"}).

![Impact of β1-AR polymorphisms on prognosis of HF.\
(A) Arg389 homozygotes vs. Gly389 carriers: all-cause mortality; (B) Arg389 homozygotes vs. Gly389 carriers: combined end-points; (C) Ser49 homozygotes vs. Gly49 carriers: all-cause mortality; (D) Ser49 homozygotes vs. Gly49 carriers: combined end-points. Gly389 carrier: including Arg389Gly and Gly389 homozygotes; Gly49 carrier: including Ser49Gly and Gly49 homozygotes; CI: confidence interval; combined end-points including death, heart transplantation and hospitalization.](pone.0037659.g004){#pone-0037659-g004}

Sensitivity Analysis {#s3e}
--------------------

The small sample studies (sample size \<100) [@pone.0037659-Podlowski1], [@pone.0037659-Liggett1] involved in our meta-analysis were deleted to reflect the influence of them on our data and conclusion. And the pooled RRs were not significantly altered, indicating that the results were robust.

Publication Bias {#s3f}
----------------

Begg's funnel plots were performed to access the publication bias of susceptibility to HF, response to β-blocker therapy and prognosis of HF. The funnel plots appeared symmetric, suggesting the absence of publication bias (data not shown).

Discussion {#s4}
==========

The purpose of diagnosing and treating HF is bringing about a reduction of mortality and morbidity. Preventive measurements can be undertaken early according to the risk factor for the development of HF, while appropriate therapeutic decision would be made by accurate prediction of response to β-blockers. Therefore, predictors of susceptibility to HF and response to β-blockers treatment are needed in clinical practice. Sustained sympathetic system activation has been shown to be deleterious to the failing heart, and the transmitters of this system, adrenaline and noradrenaline act on β-receptors situated on cardiomyocytes, which are mostly of the β1-subtype [@pone.0037659-Lohse1]. The β-blockers recommended by the guidelines -- metoprolol, bisoprolol, carvidilol can block β1- receptors as their common function [@pone.0037659-Dickstein1], [@pone.0037659-Hunt1]. Therefore, the β1 adrenergic receptor plays decisive role in the development and treatment of HF. In vitro and in vivo experiments showed that agonist-related downregulation in Gly49 variant was significantly greater than Ser49 [@pone.0037659-Levin1]. It was also found that Arg389 receptor would have a greater agonist-promoted coupling to Gs/adenylyl cyclase compared with Gly389 [@pone.0037659-Mason1], and β1 AR Arg389 desensitized more rapidly than the Gly389 variant [@pone.0037659-Rathz1]. Since the important role of β1 AR in HF, it was inferred that the two functional polymorphisms would predict the susceptibility to HF, the response to β-blockers treatment, and even the prognosis of HF. However, there was no large scale study to verify the relationship.

We have performed a meta-analysis on the impact of β1 adrenergic receptor polymorphisms on susceptibility to heart failure, response to β-blocker therapy and HF prognosis, including data on over 7000 patients and 3000 healthy controls. It has been found that Gly389 allele and Gly389 homozygote increased the risk of HF in East Asians, but trended to decrease the risk of HF in whites. Overall the response to β-blockers in Arg389 homozygote was greater than that in Gly389 carrier while the reductions of HR were similar. But the Arg389 homozygotes did not confer a significant prognosis benefit in heart failure patients. The Ser49Gly polymorphism was associated with neither risk nor prognosis of HF.

There was evidence in transgenic mice to show that Arg389 allele was a risk factor of HF [@pone.0037659-MialetPerez2], while there may be a role for the Ser49Gly polymorphism in the susceptibility to HF [@pone.0037659-Liggett2]. In the present meta-analysis, Gly49 allele increased the HF risk in the general population and in East Asians, but the result was not robust in sensitivity analysis. In the studies with the controls not in HWE, the lack of HWE indicates genotyping errors, population stratification, and selection bias, which could be potential sources of biases [@pone.0037659-Higgins1]. Recently, a meta-analysis [@pone.0037659-Jin1] found that the Gly389Gly significantly increased risk of idiopathic dilated cardiomyopathy (IDCM) in Asians, which consisted with our result. But in that study, Arg389Gly was not associated with susceptibility to IDCM in Europeans. In our study, the causes of HF included IDCM, hypertension and ischemic cardiomyopathy. The important role of Arg389Gly in essential hypertension [@pone.0037659-Li1] and LV remodeling in patients following acute myocardial infarction (AMI) [@pone.0037659-McLean1] could explain that Arg389Gly polymorphism affected the risk of HF but did not associate with susceptibility to IDCM in whites.

Furthermore, as a complex pathophysiological process, heart failure was involved in multi-genetic effection, thus other functional genes that affected the susceptibility to HF may mask the influence of β1 adrenergic receptor polymorphisms in different ethnics. In addition, environmental interactions (e.g., smoking, physical activity, and diet) may also play a role in the pathogenesis of HF [@pone.0037659-Djouss1]. In the future, the polymorphisms within haplotypes combined with environmental interactions can be a risk stratification tool of HF rather than the individual polymorphism.

Experiments in mice and healthy volunteers showed that the reduction of HR to β-blocker in Arg389 homozygotes was greater than that in Gly389 carriers [@pone.0037659-Liggett2], [@pone.0037659-Liu1]. However, in our meta-analysis the reductions of HR were comparable, which might be related with the downregulation of myocardial β1 AR in HF patients. While the improvements of LVEF and LVESd/v were significantly better in Arg389 homozygotes, which also performed a trend for greater reduction of LVEDd/v. In clinic practice, doctors treat the patient would titrate β-blockers to achieve appropriate heart rate reduction. According to the results, Arg389Gly polymorphism may be a predictor of response to β-blocker treatment in HF patients, which is independent of HR. These findings would be useful in making individualized therapeutic decision in the future.

In another subgroup analysis, the Arg389 homozygotes performed a greater LVEF improvement to selective β1-blockers therapy than Gly389 carriers, but no differences were conferred by genotypes in the patients treated with non-selective β-blockers, as non-selective β-blockers also block β2 and α1 AR. The LVEF is an important indicator of response to treatment. Blockade of the β1AR is certainly responsible for a large degree of the improvement seen in HF, such as LVEF improvement and survival benefits, but it is not the sole mechanism. Previous studies have suggested that the release of norepinephrine is partly regulated by prejunctional β2-adrenergic receptors [@pone.0037659-Azevedo1], and that α1-ARs can also increase contractility equal to β -ARs in failing hearts [@pone.0037659-Jensen1]. As the importance of β2 and α1 AR in failing hearts, the role of β1 AR in patients who were treated with non-selective beta-blockers was weakened. Thus the association between the improvement of LVEF and Arg389Gly polymorphism was not significant among patients treated with non-selective β-blockers.

As the progression of heart failure is associated with LVEF, it is expected the Arg389 homozygotes would get a better efficacy by selective β1-blockers therapy and Gly389 carriers might benefit more from non-selective β-blockers, which needs further investigation.

In a study of 54 patients with HF, individuals with the Gly49 variant had greater improvement in LVEDd [@pone.0037659-Liggett1]. However, no association between Ser49Gly polymorphism and the change of LVEF was found [@pone.0037659-Chen1], [@pone.0037659-deGroote2]. The being few studies, these findings need to be further confirmed.

Although the therapeutic response to β-blockers was influenced by the β1 AR polymorphisms, no differences were found in the prognosis of heart failure. In theory, a better beta-blocker response might lead to potential adverse outcomes, such as HF deterioration, hypotension and bradycardia. But by now, there has been no data supporting the association between the β1 genetic polymorphisms and the adverse outcomes in prognosis. It is also believed that in the failing heart the density of β AR, especially the β1 AR, kept decreasing [@pone.0037659-Brodde1]. In our meta-analysis, the follow-up time of studies on prognosis of HF was relatively longer than that of studies on β-blocker responses. Thus the density of β1-AR in studies on prognosis of HF was more decreased than that in studies on beta-blocker responses. Therefore, the β1 AR played a more important role in response to β-blockers than that in prognosis of HF. Recently, a meta-analysis [@pone.0037659-OConnor1] has shown that the patients enrolled in the United States were associated with a lower magnitude of survival benefit to β-blockade than the ones from the rest of the world. The result demonstrated that the determining prognosis in HF is complex. Besides genetic factors, the cultural or social differences in disease management may also cover the impact of β1-AR polymorphisms. In addition, the sample size would have been too small to detect the differences.

In the future, large sample clinical trials which investigate both the response to beta-blockers and prognosis in the same group of patients may make more sense for this problem.

Limitation {#s4a}
----------

First of all, we evaluated the relationships between heart failure and the two functional β1 AR polymorphisms, Ser49Gly and Arg389Gly respectively. Since the two polymorphisms are in strong linkage disequilibrium (LD) [@pone.0037659-Muthumala1], the combined effects in haplotypes may be more decisive in susceptibility to HF, response to β-blocker therapy, and prognosis.

Secondly, in the 10 studies for prognosis of HF, the percentage of patients treated with beta-blockers ranged from 70% to 100%. The non-treated cases could not be excluded so that our results would inevitably be compromised. It's a limitation of our meta-analysis. But in reality, some patients with heart failure due to the presence of contraindications cannot use β-blockers. Therefore, we believe that the current results were closer to clinical practice.

At last, the sample size for each study was relatively small, even though all the studies in which the data could be achieved were collected for analysis, yet prospective studies with large sample size are warranted.

Conclusion {#s4b}
----------

Based on the present meta-analysis, we found that the Gly389 allele and Gly389 homozygote were associated with the increasing risk of HF in East Asians; but in whites, Gly389 allele and Gly389 homozygote trended to decrease the risk of HF. The Ser49Gly polymorphism of β1 receptor was not associated with risk of HF. With the similar reduction of heart rate, overall, the Arg389 homozygotes performed a better response to β-blocker therapy. Furthermore, the Arg389 homozygotes were significantly associated with better LVEF improvement in East Asians and mixed population. And in white people, the Arg389 homozygotes made a greater LVESd/v improvement and trended to be associated with better LVEDd/v improvement. However, neither of the two β1 AR polymorphisms impacted the prognosis of HF based on our data. The results of our meta-analysis would provide a reference for individualized treatment of HF, and are also helpful in future prospective clinical trials.
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